Subject: NIH Guide, May 25, 1990
From: Dot Baker <[email-masked]>
To: [email-masked]
Date: Fri, 25 May 90 07:47 EST

Hello,
   This is the second of three items to be posted to the NIH Listserver.
Please post this one as: nihguide.052590.
   Thanks.
           Dottie
 ---------------------------- Text of forwarded message -----------------------
     
X-comment: NIH Guide (including TOC) contained 6 pages (480 lines)
X-comment: RFAs described:  CA-90-13, HG-90-01

     

     
NIH GUIDE - Vol. 19, No. 20, May 25, 1990

                   NOTICES OF AVAILABILITY (RFPs AND RFAs)

CHEMICALLY INDUCED DNA MODIFICATIONS (RFP) .............(84/119)............. 1
National Institute of Environmental Health Sciences
Index:  ENVIRONMENTAL HEALTH SCIENCES

COMMUNITY CLINICAL ONCOLOGY PROGRAM (RFA CA-90-13) ...(122/226, 484/2085).... 1
National Cancer Institute
Index:  CANCER

COURSES RELATED TO GENOMIC ANALYSIS (RFA HG-90-01) ...(241/394, 2088/2349)... 3
National Center for Human Genome Research
Index:  HUMAN GENOME RESEARCH

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     
     
                   NOTICES OF AVAILABILITY (RFPs AND RFAs)

CHEMICALLY INDUCED DNA MODIFICATIONS
     
RFP AVAILABLE:  NIH-ES-90-03
     
P.T. 34; K.W. 0760053, 1002028, 1215018
     
National Institute of Environmental Health Sciences
     
The purpose of this contract is to examine the effects of chemicals on
specific regions of the genome.  Specifically, the contractor shall examine
chemical adduction and its repair to specific genes (not to bulk DNA), and to
relate these effects to mutagenesis or carcinogenesis.  The offeror also may
propose to develop new or existing assays to examine DNA modifications at
specific regions of the genome.  The contractor shall study a total of 8
compounds both in vitro and in vivo over the duration of the contract.  The
project shall be conducted in accordance with the following standards:  NTP
Health and Safety Minimum Requirements for Contract Laboratories Performing
Work for the Systemic Toxicology Branch; NIH Guidelines for Research Involving
Recombinant DNA Molecules, Federal Register, May 7, 1986, Vol. 51, No. 88, pp.
16958-16985; and NCI Safety Standards for Research Involving Chemical
Carcinogenesis, DHHS Pub. # NIH (76-900).  The Government estimates that
approximately 2.4 professional person years and 1 technical person year will
be required on an annual basis.  A term form, level-of-effort type contract is
contemplated with an estimated period of performance of 5 years.  All
responsible sources may submit a proposal which shall be considered by the
Agency.  Expected release date of the RFP is May 24, 1990, with proposals due
July 23, 1990.
     
Requests should reference RFP NIH-ES-90-03 and should be forwarded to:
     
National Institute of Environmental Health Sciences
Contracts and Procurement Management Branch, OM
ATTN:  Marilyn B. Whaley, Contract Specialist
79 T.W. Alexander Drive, 4401 Building
P. O. Box 12874
Research Triangle Park, NC  27709

COMMUNITY CLINICAL ONCOLOGY PROGRAM
     
RFA AVAILABLE:  CA-90-13
     
P.T. 34; K.W. 0403004, 0715035, 0755015, 0795003
     
National Cancer Institute
     
Letter of Intent Receipt Date:  June 15, 1990
Application Receipt Date:  August 24, 1990
     
The Division of Cancer Prevention and Control (DCPC), National Cancer
Institute (NCI), invites applications from domestic institutions for
cooperative agreements to the Community Clinical Oncology Program (CCOP).  New
community and research base applicants and currently funded programs are
invited to respond to this Request For Applications (RFA).
     
This reissuance of the CCOP RFA seeks to build on the strength and
demonstrated success of the CCOP over the past seven years by:  1) continuing
the program as a vehicle for supporting community participation in treatment
and cancer control clinical trials through research bases (clinical
cooperative groups and cancer centers supported by NCI, and public health
departments); 2) expanding and strengthening the cancer control research
effort; 3) utilizing the CCOP network for conducting NCI-assisted cancer
control research; and 4) evaluating on a continuing basis CCOP performance and
its impact in the community.
     
BACKGROUND INFORMATION
     
Over 80 percent of patients with cancer are treated in the community.  The
CCOP was initiated in 1983 to bring the benefits of clinical research to
cancer patients in their own communities by providing support for physicians
to enter patients onto treatment research protocols.  The CCOPs clearly were
very effective in accruing patients to treatment clinical trials.  The second
RFA, issued in 1986, expanded the focus to include cancer control research.

     
              NIH GUIDE - Vol. 19, No. 20, May 25, 1990 - Page 1
The development of cancer control research in the CCOP network has been
increasing steadily since funding began in 1987.  Protocols are developed by
the research bases and reviewed by DCPC's Cancer Control Protocol Review
Committee (CCPRC).  Protocols cover the full spectrum of cancer control
research, including chemoprevention, marker studies, smoking cessation
studies, screening and early detection, and pain control and other supportive
care interventions aimed at reducing cancer incidence, morbidity, and
mortality.
     
RESEARCH GOALS AND SCOPE
     
The CCOP initiative is designed to:
     
  o  Bring the advantages of state-of-the-art treatment and cancer
     control research to individuals in their own communities by having
     practicing physicians and their patient/subjects participate in
     NCI-approved treatment and cancer control clinical trials;
     
  o  Provide a basis for involving a wider segment of the community in
     cancer control research;
     
  o  Increase the involvement of primary health care providers and other
     specialists with the CCOP investigators in treatment and cancer
     control research;
     
  o  Facilitate wider community participation, including minorities,
     women, and other underserved populations, in treatment and cancer
     control research approved by NCI; and
     
  o  Reduce cancer incidence, morbidity, and mortality by accelerating
     the transfer of newly developed cancer prevention, early detection,
     treatment, patient management, rehabilitation, and continuing care
     technology to widespread community application.
     
There will be two types of grantees:  community programs and research bases.
Community applicants may be a hospital, a clinic, a group of practicing
physicians, a health maintenance organization (HMO) or a consortium of these.
Community programs (CCOPs) will be required to enter patients onto
NCI-approved treatment and cancer control clinical trials through the research
base(s) with which each CCOP is affiliated.
     
Research base applicants must be either an NCI-funded clinical trials
cooperative group or cancer center or a public health department.  Research
bases will be required to provide clinical research treatment and/or cancer
control protocols, monitor the quality of protocol conduct, and follow CCOP
accrual.
     
MECHANISM OF SUPPORT
     
CCOP and research base awards will be made as Cooperative Agreements.  The
cooperative agreement is an assistance mechanism involving cooperation by NCI
staff as described in the RFA.  It is anticipated that up to $4.4 million in
total costs per year for 5 years will be committed to specifically fund
applications which are submitted in response to this RFA.  Of the total,
approximately $3.9 million will be committed to research bases and
approximately $450,000 to CCOPs.  It is anticipated that up to 17 research
base awards and up to 5 CCOP awards will be made.  Awards will be for three,
four, or five years as described in the RFA.
     
STAFF CONTACT
     
Leslie G. Ford, M.D.
Community Oncology and Rehabilitation Branch, DCPC, NCI
Executive Plaza North, Room 300-D
National Institutes of Health
Bethesda, MD  20892

     

     

     

     
     
              NIH GUIDE - Vol. 19, No. 20, May 25, 1990 - Page 2
COURSES RELATED TO GENOMIC ANALYSIS
     
RFA AVAILABLE:  HG-90-01
     
P.T. 44; K.W. 1215018, 0755045, 0720005, 0710030, 1002058, 1004017, 1014004
     
National Center for Human Genome Research
     
Application Receipt Date:  August 24, l990
     
The National Center for Human Genome Research invites applications for support
of short, advanced-level courses emphasizing new laboratory techniques in
genome analysis, informatics as it relates to the human genome, principles of
genomic analysis for scientists trained in fields other than biology or
scholars trained in the humanities, social sciences, or law and principles and
methods of studying the social, ethical and legal issues relevant to the human
genome program.  These courses are meant to enhance the skills of individuals
interested in pursuing laboratory or scholarly research relevant to the goals
of the Human Genome Program.
     
BACKGROUND
     
For the genome project and the field of genomic research to develop rapidly
enough to meet these goals in a timely and cost-effective manner, it will be
necessary to disseminate technological advances and new information as rapidly
as possible and to recruit scientists from many disciplines, both biological
and non-biological, into this research area.  The development of many fields,
such as molecular biology and genetics, has been enormously abetted by the
availability of short, intensive, advanced level courses.  Properly designed
courses in areas of relevance to genomics could be of similar utility to the
development of the genome project itself and to the application of the
information produced by the project.
     
RESEARCH OBJECTIVE
     
The goal of this Request for Applications (RFA) is to stimulate the
development of courses in subjects relevant to the Human Genome Program and
appropriate to the broader scientific community.  The following list of
potential subjects for such courses is not intended to be limiting but to
provide examples.  The goal of each course should be to improve the level of
the cross-disciplinary training of practicing scientists and other
professionals to enable them to participate more effectively in the Human
Genome Program and to utilize the information and technology produced by the
Human Genome Program in other areas.
     
  o  Important techniques, including new technological developments
     relevant to genomic analysis.  Examples of techniques that could be
     included are automated DNA sequencing, use of large fragment
     cloning vectors such as yeast artificial chromosomes, experimental
     mouse genetics, linkage analysis, or in situ fluorescence
     cytogenetics.  Courses of this type should be addressed to
     practicing biologists who wish to learn new skills;
     
  o  Various aspects of informatics as they relate to the Human Genome
     Program.  Examples include data management, database design,
     algorithm development for map and/or sequence assembly.  Such
     courses should be addressed to biologists who wish to become
     conversant with informatics;
     
  o  Principles of genetics as related to current issues of genomic
     analysis.  Such courses would be directed at scientists trained in
     other disciplines, such as mathematics, information science,
     computer science, physics, chemistry or engineering, interested in
     applying their skills to the scientific problems raised by the
     Human Genome Program;
     
  o  Principles of genetics and genomic analysis for scholars trained in
     appropriate areas of the humanities, social sciences and law who
     are interested in examining the social, ethical and legal
     ramifications of the acquisition of detailed information about the
     human genome;
     
  o  Principles and approaches for the analysis of ethical, legal and
     policy issues related to human genome research, including
     historical and social perspectives.  Such courses should be
     designed for biologists and health professionals who are interested
     in contributing their expertise to a multidisciplinary approach to
     these issues.
     
              NIH GUIDE - Vol. 19, No. 20, May 25, 1990 - Page 3
Courses should be designed to address the needs and interests of advanced
graduate students, post-doctoral trainees, established scientists and other
professionals who want to learn particular new skills or become more
knowledgeable about genomic research in order to pursue research problems
relevant to the Human Genome Program.  Efforts should be made to select for
participation students who are currently under-represented in the field of
genomic research such as women and under-represented minorities.  Courses will
typically be one to two weeks in length and offered annually, although other
terms will be acceptable.  Applicants may initially request support for two
years.  Course offerors are expected to be academic or research institutions
experienced in training and faculty are expected to consist of established
investigators or scholars actively working in the area of instruction.
     
MECHANISM OF SUPPORT
     
Support for this program will be through the Continuing Education Training
Grant mechanism (T15).  Policies that govern research grant programs of the
NIH apply to this program.  It is anticipated that up to six awards will be
made.
     
APPLICATION AND REVIEW PROCEDURES
     
Only domestic institutions are eligible to apply for support under this
announcement.  These applications will be reviewed within the National Center
for Human Genome Research for both initial review and final review.
     
Review criteria include the following:
     
  o  Overall scientific and didactic merit;
     
  o  Potential value of the course for furthering the training goals of
     the Human Genome Program, including, when appropriate, the
     potential effectiveness in attracting scientists and scholars into
     working on problems important for the success of the genome
     project;
     
  o  Quality of the course content and adequacy of the syllabus;
     
  o  Training, experience and research competence of the faculty;
     
  o  Criteria for selecting participants;
     
  o  Plans for publicizing the availability of courses to the
     appropriate community of scholars and scientists;
     
  o  Adequacy of available facilities including the library;
     
  o  Appropriateness of the requested budget for the proposed course.
     
METHOD OF APPLYING
     
Applications should be submitted on Form PHS 398 (rev.  10/88).  The RFA label
available in the revised application kit must be affixed to the bottom of the
face page.  The original and six copies of the application should be submitted
to:
     
Grant Application Receipt Office
Division of Research Grants
Westwood Building, Room 240
Bethesda, MD  20892**
     
Applications received in August will be reviewed for scientific merit in
October/November 1990, and will be considered by a National Advisory Council
or Board for the NCHGR in January 1991.  The earliest an award can be made is
April 1, 1991.
     
Inquiries:  Prospective applicants are encouraged to contact the program
official below to discuss this RFA.
     
Bettie J. Graham, Ph.D.
Building 38A, Room 613
National Center for Human Genome Research/NIH
Bethesda, MD  20892
Telephone:  (301) 496-7531

     

              NIH GUIDE - Vol. 19, No. 20, May 25, 1990 - Page 4
**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF
RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS THE
CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH.  APPLICANTS WHO
USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S
REQUIREMENTS FOR SHOWING A STREET ADDRESS.  THE ADDRESS FOR THE WESTWOOD
BUILDING IS:
     
5333 Westbard Avenue
Bethesda, Maryland 20816

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     
     
              NIH GUIDE - Vol. 19, No. 20, May 25, 1990 - Page 5